Document is current
Any future updates will be listed below
-
Authors
Aguirre, Luis E. https://orcid.org/0000-0002-5377-9252
Stone, Richard M. https://orcid.org/0000-0002-7526-2633
DeAngelo, Daniel J. https://orcid.org/0000-0001-7865-2306
Stahl, Maximilian
- License Information
-
More Information
Article History
Received: 16 September 2025
Revised: 22 September 2025
Accepted: 24 October 2025
First Online: 4 November 2025
Competing interests
: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Luis E. Aguirre reports consultancy for Curio Science, Cardinal Health, Research To Practice. Honoraria from Curio Science, Fast4ward Learning, Cardinal Health, DAVA Oncology. Richard M. Stone reports research funding from Janssen and AbbVie; Consultancy for GlaxoSmithKline, Curis Oncology, Daiichi Sankyo, ENSEM, Epizyme, BerGenBio, AMGEN, Syntrix, Hermavant, Glycomimetrics, CTI Biopharma, Bristol Meyers Squibb, Rigel, Syndax, AvenCell, Takeda, Jazz, Kura Oncology, Lava Therapeutics, Cellarity, Ligand Pharma, Novartis, Aptevo, and Redona therapeutics; Other: DSMB for Epizyme, Syntrix, Takeda, and Novartis. Daniel J. DeAngelo reports consultancy for Kite, Servier, Incyte, Pfizer, Gilead, Novartis, Jazz, Autolos, Amgen, and Blueprint; Honoraria from Amgen and Bristol-Meyers Squibb; Research funding from Servier, Novartis, Glycomimetics, AbbVie, and Takeda; Other: DSMB for MT Sinai MPN Consortium, Fibrogen, Daiichi-Sankyo. Maximilian Stahl reports membership on the Board of Directors or advisory committees for GSK, Rigel, Sobi, Sierra Oncology, Kymera, BMS, and Syndax. No other disclosures were reported.
